Why Illumina Might Be Offering a Lucrative Investment Opportunity

Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as Illumina (ILMN) missed analysts’ expectations and its own projections regarding its revenues. Prior to the announcement of its Q1 results, the giant gene sequencing firm offered investors a comprehensive explanation of the origin of the miss and the actions it has already begun to take to avoid future misses. Illumina pinpointed the HiSeq arrays that had declining sales and the reasons for the miss and the region where the sales decline has occurred.

It was not all negative news . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.